Rybelsus vs Ozempic: what’s the difference?

Interest in pharmacological treatment for obesity and metabolic disease has grown significantly in recent years, and semaglutide is one of the most widely studied and commonly used substances in this area.

Because semaglutide is available both as a tablet and as an injection, it’s natural to wonder about the differences in effect, use and suitability. Is a weekly injection more effective than a daily tablet? And how do dose, indication and individual tolerance affect the choice of treatment?

Below is an overview of the similarities and differences between the options.

Same substance, different formats

Rybelsus, Ozempic and Wegovy all belong to the group of medicines known as GLP-1 receptor agonists and contain the same active substance: semaglutide.

This means they have the same basic mechanism of action in the body:

• Increased fullness: Semaglutide activates GLP-1 receptors in the parts of the brain that regulate appetite, which can help you feel full sooner and for longer.
• Reduced hunger and cravings: Many people experience a reduced appetite and fewer repeated hunger signals.
• Delayed stomach emptying: The stomach empties more slowly, which can increase fullness and help support steadier blood sugar levels after meals.

Semaglutide also stimulates glucose-dependent insulin release and reduces glucagon secretion when blood sugar levels are high, which helps improve blood sugar control in type 2 diabetes.

The key difference between Ozempic and Rybelsus is how they’re taken.

Ozempic is given as a subcutaneous injection once a week.

Rybelsus is an oral GLP-1 receptor agonist taken as a tablet once a day. Because peptide medicines are normally broken down in the digestive system, Rybelsus contains an absorption enhancer called sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, or SNAC. SNAC protects semaglutide from being broken down in the stomach and helps it to be absorbed through the stomach lining.

Both Ozempic and Rybelsus are approved for the treatment of type 2 diabetes alongside changes to diet and physical activity.

For the treatment of obesity, a different dosing regimen of semaglutide is used under the brand name Wegovy, which is specifically approved for weight management. Rybelsus is not currently approved for the treatment of obesity. In some cases, doctors may consider so-called off-label prescribing, which means using a medicine outside its approved indication after an individual medical assessment.

Both Ozempic and Rybelsus are developed by Novo Nordisk.

Which option has the best effect on weight?

Many people wonder whether the injection is more effective than the tablet. Clinical studies show that both forms can give good results for weight loss.

• Rybelsus: In the OASIS-1 study, in people with overweight or obesity without diabetes, the average weight loss was around 15% after 68 weeks with a 50 mg dose.

• Wegovy: In the STEP-1 study, where injectable semaglutide 2.4 mg, Wegovy, was used for obesity, the average weight loss was also around 15% after 68 weeks.

The conclusion is that tablet treatment can be a very effective alternative to injections, as long as the dosing instructions are followed carefully.

Comparison of characteristics and use for weight loss

Rybelsus and Wegovy differ in how they’re taken and managed in everyday life. These differences can affect which option is the better fit for an individual.

How they’re taken

• Rybelsus is taken as a tablet once a day.
• Wegovy is given as a subcutaneous injection once a week, usually in the stomach area, thigh or upper arm. The medicine comes in a pre-filled injection pen.

Dosing frequency and flexibility

• Rybelsus needs to be taken daily on an empty stomach to make sure enough of the medicine is absorbed.
• Wegovy is taken once a week and can be given at any time of day, regardless of meals.

How to take Rybelsus

Because oral semaglutide has naturally low bioavailability, it needs to be taken in a specific way:

• The tablet should be taken in the morning after at least 8 hours of fasting.
• It should be swallowed with up to around 120 ml of water.
• You should wait at least 30 minutes before eating, drinking or taking any other medicines.

Taking food or drink at the same time can reduce the absorption of semaglutide.

In people who have had certain types of bariatric surgery, the absorption of oral medicines may be altered, which should be taken into account in an individual medical assessment.

Who may Rybelsus suit best?

Rybelsus may be a suitable option for people who prefer tablets rather than injections, for example if they have a strong fear of needles or want to avoid weekly injections.

Because the medicine can be stored at room temperature, it may also feel practical for people who travel often or in situations where refrigerated storage is less accessible.

At the same time, oral semaglutide requires a clear and consistent morning routine. To make sure enough of the medicine is absorbed, the tablet must:

• be taken on an empty stomach after at least 8 hours of fasting
• be swallowed with up to around 120 ml of water
• be followed by at least 30 minutes of waiting before eating, drinking or taking other medicines

This treatment routine places higher demands on daily adherence than a weekly injection. For some people this works well, while others may find weekly dosing easier to fit into everyday life.

The choice should therefore be based on an individual medical assessment, life circumstances and personal preferences.

Side effects, warnings and precautions

Because both Ozempic and Rybelsus contain semaglutide, their side effect profile is largely similar. The most common side effects are related to the digestive system and are linked to how the medicine works.

Common side effects

The most commonly reported side effects are:

• Nausea
• Diarrhoea
• Constipation
• Vomiting
• Bloating

Digestive side effects are most common at the start of treatment or when the dose is increased, and they are usually mild to moderate. For most people, these symptoms improve over time as the body adjusts. Gradual dose increases are an important part of treatment to improve tolerability.

Hypoglycaemia

Semaglutide on its own carries a low risk of hypoglycaemia. The risk does increase, however, if it is used at the same time as insulin or sulfonylureas. In these cases, the dose of other blood sugar lowering treatment may need to be adjusted, and people should be informed about the symptoms of low blood sugar.

Pancreatitis

In rare cases, acute pancreatitis has been reported during treatment with GLP-1 receptor agonists. Ongoing and severe pain in the upper abdomen, especially if it spreads to the back, requires immediate medical assessment and treatment should be stopped if pancreatitis is suspected.

Diabetic retinopathy

Caution should be used when semaglutide is given to people with diabetic retinopathy. These people should be monitored carefully and treated in line with clinical guidelines. Good long-term blood sugar control reduces the risk of diabetic retinopathy.

Contraindications and general precautions

Semaglutide should not be used in people with known hypersensitivity to the active substance or any of the excipients.

Caution should also be used in severe gastrointestinal disease, previous pancreatitis or other relevant health conditions. Any other medicines being taken should always be considered.

Treatment should take place under medical supervision to make sure dosing is correct, any side effects are managed and the balance between risks and benefits is carefully assessed.

Dosing and administration

Wegovy is indicated for weight management in adults with obesity, or with overweight and a weight-related health condition, alongside lifestyle changes. The medicine is given as an injection once a week.

The active substance is semaglutide, a GLP-1 receptor agonist that helps support blood sugar regulation and weight loss in people with type 2 diabetes, Ozempic, and obesity, Wegovy.

Treatment usually starts with a dose of 0.25 mg once a week during the first four weeks. The dose can then be increased if needed to 0.5 mg once a week for additional effect. If the effect is not enough, the doctor may decide to increase the dose further. It’s important to always follow your doctor’s instructions on dosing and administration, and never change the dose yourself.

People who are pregnant, breastfeeding or planning a pregnancy should speak to a doctor before starting treatment. The medicine should never be shared with anyone else and should always be stored according to Novo Nordisk’s instructions.

Rybelsus is also a medicine that contains the active substance semaglutide and is used to treat insufficiently controlled type 2 diabetes mellitus alongside changes to diet and physical activity. Unlike Ozempic and Wegovy, Rybelsus is taken as a tablet once a day, usually on an empty stomach after at least eight hours of fasting. The tablet should be taken with up to 120 ml of water, and after taking it you should wait at least 30 minutes before eating, drinking or taking any other medicines to make sure absorption is as good as possible.

Treatment with Rybelsus starts with a low dose to reduce the risk of side effects, and the dose can then be increased in line with your doctor’s instructions. Just as with Ozempic, it’s important to follow your doctor’s dosing recommendations carefully.

Rybelsus is not recommended for children and young people under 18 years of age. People who are pregnant, breastfeeding or planning a pregnancy should speak to a doctor before starting treatment. Both Ozempic, Wegovy and Rybelsus should be used as part of a treatment plan that also includes lifestyle changes such as diet and physical activity for the best possible effect. If you have questions about how to use the medicine or about dosing, you should contact your doctor.

Summary

Rybelsus and Ozempic contain the same active substance, semaglutide, and have the same basic mechanism of action. The main difference lies in how they’re taken, a daily tablet or a weekly injection, as well as in dose levels and approved indications.

For the treatment of obesity, higher doses of semaglutide are used under the name Wegovy, while Rybelsus is approved for type 2 diabetes. Clinical studies show that both oral and injectable semaglutide can lead to significant weight loss, but the size of the effect is influenced by dose, indication and individual treatment response.

The choice between treatments should be based on medical assessment, treatment goals, tolerance and practical circumstances. For the best results, medication should always be combined with structured lifestyle support and regular follow-up.

How Yazen works

Food and physical activity are core parts of obesity treatment and should always be followed alongside medical treatment for the best possible results.

Whether treatment is with a tablet or an injection, the medicine is a tool, not a standalone solution. Sustainable weight loss depends on a structured treatment plan where medication is combined with lifestyle support.

At Yazen, treatment is based on an individual medical assessment where the choice of medicine depends on your medical circumstances, treatment goals and tolerance. The principle of using the lowest effective dose is applied to achieve good results with the best possible tolerability.

Treatment is combined with ongoing follow-up and support around food, physical activity and behaviour change. The goal is safe, evidence-based and sustainable treatment over time, whether the choice is Rybelsus, Wegovy or another medical treatment.

Sources

EMA, Ozempic (semaglutide) Prescribing Information
https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic

EMA, Rybelsus: EPAR Product Information (semaglutide)
https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus

The New England Journal of Medicine, Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 Trial)
https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

Reviews in Endocrine and Metabolic Disorders, A New Era for Oral Peptides: SNAC and the Development of Oral Semaglutide for the Treatment of Type 2 Diabetes
https://pmc.ncbi.nlm.nih.gov/articles/PMC9515042/

The Lancet, OASIS-1 Trial: Oral Semaglutide 50 mg for Weight Loss
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01185-6/abstract

‍